Delcath Systems, Inc.
NASDAQ:DCTHMedical - Devices
-$0.23 today
- Market cap
- $669.32M
- Beta
- 0.52
- P/E (TTM)
- 751.4
- EPS (TTM)
- $0.02
Volume 0.46M
Average 0.42M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
Delcath Systems, Inc.
NASDAQ:DCTH
Intrinsic Alpha fair value
Locked
Current Price
$19.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | +75.6% (5yr)1 analysts |
| Revenue | N/A | N/A | +215.3% | +22.2% (5yr)2 analysts |
| Net Income | N/A | N/A | N/A | +75.6% (5yr)2 analysts |
| EBIT | N/A | N/A | N/A | +144.4% (5yr)2 analysts |
Analysis
Recent growth has been strongest in Revenue at +215.3% over three years. Forward estimates point to EBIT at +144.4% (5yr), giving you a quick check on whether expectations are accelerating or cooling.
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
NovoCure Limited NASDAQ:NVCR | $1.38B | $11.83 | Not rated | -9.5 | -6.72% |
TriSalus Life Sciences, Inc. NASDAQ:TLSI | $149.93M | $2.43 | Not rated | -7.4 | -56.15% |
Perspective Therapeutics, Inc. AMEX:CATX | $113.89M | $0.94 | Not rated | -0.0 | -63.02% |
Continue the stock analysis
Jump to another research area for this company.